Drug intelligence / Profile preview

MT104 (Mthera Pharma)

Development stage: Preclinical
Lead developer: Mthera Pharma
Modality: Small Molecules

Overview

MT104 is an investigational drug candidate being developed by Mthera Pharma for the treatment of ischemic cerebrovascular disease. It is developed using Mthera's proprietary Multi-Component Multi-Target (MCMT) technology platform, which utilizes systems biology and artificial intelligence to identify and optimize synergistic combinations of components that can modulate multiple biological pathways simultaneously. While the specific molecular targets and chemical identity of MT104 have not been publicly disclosed, the MCMT approach typically focuses on standardized botanical extracts or multi-constituent small molecule formulations. The candidate is currently in the preclinical or early human application stage of development.

Beyond the preview

Go deeper on MT104 (Mthera Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT104 (Mthera Pharma).

Explore the full profile